IPSEN BIOPHARM LIMITED

Active
Company number 01653765Private limited companyIncorporated 1982

Key figures

£588,218,000-4.6%
Net assets 2025
-4.6%
Average annual change 2024–2025
0200 m400 m600 m800 m20242025

† IPSEN BIOPHARM LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.

Ratios

2025

Sector comparison

SIC 21100

Where the company stands among the 1,055 active companies whose first SIC code is 21100 (Manufacture of basic pharmaceutical products).

Turnover£697,406,000
Higher than 96% · median £23,360,137 among 97 that publish turnover
Net assets£588,218,000
Higher than 99% · median £41,497
Total assets£936,814,000
Higher than 99% · median £308,978
Employees773
Higher than 99% · median 1
Company age44.3 years
Older than 92% · median 9.0 years
Largest in this sector by net assets
  1. GE HEALTHCARE LIMITED£5.6bn
  2. THERMO FISHER SCIENTIFIC LIFE HOLDINGS LIMITED£1.4bn
  3. LRC PRODUCTS LIMITED£1bn
  4. SMITHKLINE BEECHAM LIMITED£940m
  5. DECHRA LIMITED£780.1m
  6. IPSEN BIOPHARM LIMITED£588.2m
  7. ORTHO-CLINICAL DIAGNOSTICS£295.7m
  8. BESPAK EUROPE LIMITED£256m
  9. SEQIRUS VACCINES LIMITED£254.2m
  10. IOVANCE BIOTHERAPEUTICS UK LTD£199.7m

Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 1,055. The line on each bar marks the median.

Summary: IPSEN BIOPHARM LIMITED

What kind of company is it?

IPSEN BIOPHARM LIMITED is a private limited company registered with Companies House under company number 01653765. It was incorporated on 23 Jul 1982. Its status is active. The registered office is in Wrexham (LL13). Its nature of business (SIC 2007) is manufacture of basic pharmaceutical products (21100).

How is the company doing financially?

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files full accounts. Turnover was £697,406,000. Profit for the year was £156,965,000. Net assets were £588,218,000, down 4.6% on the previous year. Total assets were £936,814,000 and total liabilities £321,055,000. The company had an average of 773 employees. Figures are available for 2 financial years (2024–2025).

How does it compare with similar companies?

Compared with 1,055 active companies whose first SIC code is 21100: By turnover it ranks higher than 96% of the 97 that publish turnover (median £23,360,137). By net assets it ranks higher than 99% of them (median £41,497). By total assets it ranks higher than 99% of them (median £308,978). By number of employees it ranks higher than 99% of them (median 1). It is older than 92% of them (median age 9.0 years).

Has it received government grants?

It is recorded as the recipient of 3 central government grants worth £2.7m, mainly from Department for Business, Energy and Industrial Strategy.

What do public registers and reports show?

It appears on the Home Office register of licensed sponsors (Global Business Mobility: Senior or Specialist Worker, Skilled Worker). HMRC lists it as an importer of goods, mainly pharmaceuticals, miscellaneous chemicals, plastics. HMRC lists it as an exporter of goods, mainly pharmaceuticals, optical, medical and measuring instruments, iron and steel articles. In its latest payment practices report it took an average of 31 days to pay suppliers, and 28% of invoices were not paid within agreed terms. Its gender pay gap report for 2025/26 shows median hourly pay for women 3.2% lower than for men. It has a modern slavery statement on the government registry.

Who runs and controls the company?

One person with significant control is registered.

When are its next filings due?

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 17 Oct 2027.

Filed accounts2024–2025
2024 †2025 †
Turnover—697,406,000
Profit for the year—156,965,000
Total assets1,012,179,000936,814,000
Total liabilities366,368,000321,055,000
Net assets / total equity616,862,000588,218,000
Average number of employees713773

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Government grants

3 grants

IPSEN BIOPHARM LIMITED is recorded as the recipient of 3 central government grants since 2023, together worth £2.7m.

Funders
Department for Business, Energy and Industrial Strategy
1 grant · £2.5m
Department for Science, Innovation and Technology
2 grants · £200k
Grants
  1. LSIMFDepartment for Business, Energy and Industrial Strategy · £2,500,000 · Life Sciences Innovation Manufacturing Fund ('LSIMF')
  2. LSIMFDepartment for Science, Innovation and Technology · £100,000 · Life Sciences Innovation Manufacturing Fund ('LSIMF')
  3. LSIMFDepartment for Science, Innovation and Technology · £100,000 · Life Sciences Innovation Manufacturing Fund ('LSIMF')

From the Government Grants Register published by the Cabinet Office (financial years 2016/17 onwards, Open Government Licence v3.0). It covers grants from central government departments and their agencies where the register states the recipient's company number and the recipient name matches this company; grants from local authorities, lottery distributors and devolved governments are not included.

Statutory reporting

Payment practices1 Jan 2026 – 30 Jun 2026
Average time taken to pay invoices
31 days
Invoices not paid within agreed terms
28%
Standard payment terms
30–60 days
Member of a payment code
No
  • Within 30 days 61%
  • 31 to 60 days 32%
  • After 60 days 7%
Earlier periods (7)
Period ending
Days to pay
Within 30 days
Late
31 Dec 2025
28
67%
26%
30 Jun 2025
34
56%
23%
31 Dec 2024
35
61%
23%
30 Jun 2024
32
66%
21%
31 Dec 2023
32
67%
22%
30 Jun 2023
30
66%
29%
31 Dec 2022
30
64%
28%

View the latest report on GOV.UK

Gender pay gap2025/26
Median hourly pay
women 3.2% lower
Mean hourly pay
women 0.2% higher
Median bonus pay
women 2.6% lower
Employer size
500 to 999 employees
Lower pay quarter54% womenLower middle46.5% womenUpper middle44.4% womenUpper pay quarter51.3% women
Earlier years (8)
Year
Median hourly pay
Mean hourly pay
2024/25
women 2.6% lower
women 1.1% lower
2023/24
women 4.4% lower
women 4.2% lower
2022/23
women 7% lower
women 14.8% lower
2021/22
women 6.8% lower
women 20.3% lower
2020/21
women 6% lower
women 22.7% lower
2019/20
women 5.4% lower
women 17.7% lower
2018/19
women 2.7% lower
women 7.4% lower
2017/18
women 9.1% lower
women 11.9% lower

A positive gap means women's average hourly pay is lower than men's across the whole employer; it is not a comparison of pay for the same work. View on the Gender pay gap service

Modern slavery statements1
2021
Statement · summary on GOV.UK

Figures the company reported itself to the government's Check payment practices service, Gender pay gap service and Modern slavery statement registry (Open Government Licence v3.0). Only large companies and employers with 250 or more staff have to report, so most companies have nothing here.

Registers and licences

Sponsor licence‡
Licence type and rating
Worker (A rating)
Routes
Global Business Mobility: Senior or Specialist Worker, Skilled Worker

On the Home Office register of licensed sponsors, which lists organisations licensed to sponsor workers from overseas.

International trade‡

Listed by HMRC as an importer of goods in 12 of the last 12 months on record, most recently August 2026. Main goods: pharmaceuticals, miscellaneous chemicals, plastics, machinery and optical, medical and measuring instruments.

Listed by HMRC as an exporter of goods in 12 of the last 12 months on record, most recently August 2026. Main goods: pharmaceuticals, optical, medical and measuring instruments, iron and steel articles, machinery and miscellaneous chemicals.

From HMRC's monthly lists of importers and exporters. Traders can ask to be left off the lists, so absence does not mean a company does not trade.

Sources: Charity Commission for England and Wales, Care Quality Commission, Home Office and HM Revenue & Customs, under the Open Government Licence v3.0. Entries marked ‡ come from lists that do not state a company number and were linked by an exact match on the registered name.

History

4 events
  1. Financial year 2025 endedAccounts: turnover £697.4m, net assets £588.2m, 773 employees
  2. Financial year 2024 endedAccounts: net assets £616.9m, 713 employees
  3. Ipsen Developments Limited registered as a person with significant control
  4. Company incorporatedPrivate limited company

Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.